Werewolf Therapeutics

HOWL

Biotechnology · Healthcare

Price

$0.43

+0.07 (+18.55%)

Market Cap

$20.8M

Exchange

NASDAQ Global Select

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+153.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 18.5M (2021) → 46.8M (2025)

Werewolf Therapeutics is a small biotech company that develops experimental cancer drugs. It focuses on a type of medicine called "conditionally activated" immunotherapies — treatments designed to switch on only inside tumors, rather than throughout the whole body. The goal is to make powerful cancer-fighting drugs safer by reducing side effects in healthy tissue.

The company earns no product revenue yet, as all of its drug candidates are in early-stage clinical trials. It is based in Cambridge, Massachusetts, and funds its research through partnerships with larger pharmaceutical companies and by raising money from investors. Like most early-stage biotechs, Werewolf has no approved products and spends significantly more than it earns, reflected in its deeply negative returns. The main risk is that its drug candidates could fail in clinical trials, which would threaten the company's ability to continue operating without raising additional capital.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+30.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$45M/ year

↓ Declining (-21% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

12.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~13 months

$46M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-21.9%

Weak — -21.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

2.36

Heavy debt load (2.36)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial